Cat. No. 2423

DAPTA D-Ala-Ser-Thr-Thr-Thr-Asn-Tyr-Thr-NH2

Price and Availability

For DAPTA pricing & availability please select your country from the drop down menu:
By clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy.

Alternative Name: D-Ala-peptide T-amide

Biological Activity

Chemokine receptor 5 (CCR5) antagonist. Acts as a selective viral entry inhibitor for R5 tropic HIV-1 strains. Blocks CCR5-mediated monocyte chemotaxis and reduces microglia and astrocyte activation in a neuroinflammatory rat model of Alzheimer's disease.

Technical Data


(Modifications: Ala-1 = D-Ala, Thr-8 = C-terminal amide)

Soluble to 1 mg/ml in water
Desiccate at -20°C

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.

Certificate of Analysis / Safety Data Sheet

Certificate of Analysis: View current batch
Select another batch:
Safety Data Sheet: View Safety Data Sheet


Ruff et al (2003) Update on D-ala-peptide T-amide (DAPTA): a viral entry inhibitor that blocks CCR5 chemokine receptors. Curr.HIV.Res. 1 51. PMID: 15043212.

Polianova et al (2005) Chemokine receptor-5 (CCR5) is a receptor for the HIV entry inhibitor peptide T (DAPTA). Antiviral Res. 67 83. PMID: 16002156.

Rosi et al (2005) Chemokine receptor 5 antagonist D-Ala-peptide T-amide reduces microglia and astrocyte activation within the hippocampus in a neuroinflammatory rat model of Alzheimer's disease. Neuroscience 134 671. PMID: 15979806.

If you know of a relevant citation for this product please let us know.

View Related Products by Target

View Related Products by Product Action

Keywords: DAPTA, supplier, Chemokine, receptor, 5, CCR5, antagonists, CXCR, Receptors, antiviral, Rantes, Chemokine Receptor Antagonists

Quick Order

Find multiple products by catalog number

divider line

Immunology Guide


Highlights over 190 products for immunology research. Request copy or view PDF today.

divider line

New Therapies and Challenges in Asthma

Written by Peter J. Barnes

Asthma Life Science Poster

'New Therapies, Challenges, and Breakthroughs in Asthma' highlights key pathways and new therapies used to treat asthma, including those currently in clinical development. Request copy today.

divider line

VEGF Pathway & Anti-Angiogenic Therapy

Written by N. Ferrara & Y. Crawford

Angiogenesis Life Science Poster

A summary of antiangiogenic therapies targeting the VEGF pathway and the mechanisms of therapy resistance. Request copy today.

divider line

New Products in this Area

MRS 2905

Potent and selective P2Y14 receptor agonist


Potent prostacyclin (PGI2) analog

S 18886

Potent thromboxane A2 (TP) antagonist


Potent Smo antagonist

ONO 8130

EP1 receptor antagonist

TC-G 1008

Potent and selective GPR39 agonist

Ro 1138452 hydrochloride

Selective prostacyclin IP receptor antagonist

Sign-up for new product e-alerts
divider line

Twitter Updates

Follow @Tocris on Twitter

Follow us on Twitter!

Tocris is now actively tweeting. For regular updates on news, events and special offers, follow @Tocris on Twitter.